Dental equipment pioneer Henry Schein announced that it has completed the acquisition of Shield Healthcare Inc. Shield Healthcare Inc. is a device company that directly provides home care medical products to patients. Henry Schein announced this transaction last year. 01 Enters the field of household appliances In August 2023, Henry Schein announced that he had signed an agreement to acquire a majority stake in Shield Healthcare, Inc. On the basis of Henry Schein’s acquisition of Prism Medical Products LLC in 2021, Shield Healthcare will expand Henry Schein’s existing medical business by providing diversified product series, including incontinence, urology, ostomy, enteral nutrition, advanced wound care and diabetes products. In addition, it will provide patients with continuous blood glucose monitoring devices directly at home. As the healthcare industry continues to shift towards home care, we have expanded our business of directly providing medical products to patients through our partnership with Shield Healthcare, ...
After Edward Life Sciences (hereinafter referred to as Edward) sold its intensive care business to Becton DickinsonMedical for $4.2 billion, a major global layoff has begun. Approximately 3% of employees will be affected by this layoff, and according to proportional calculations, about 540 employees will be laid off. Edward CEO Bernard Zovighian stated that employees affected by the global layoffs have received notice today that some employees may temporarily stay to assist with the transformation of the intensive care business, while others may find other jobs within the company. 30.4 billion yuan sale, 4500 employees join Becton Dickinson Edward is deeply engaged in the fields of global structural heart disease, intensive care, and surgical monitoring. Currently, he has multiple advanced products such as heart valves, cardiac intervention therapy equipment, cardiac monitoring equipment, and surgical tools. Among them, with the “world’s first successfully implanted artificial mitral valve”, Edward firmly occupies the ...
In the gift recovery market, the prices of An Gong Niu Huang Wan and Pian Zi Huang, which have remained strong, have begun to fall in the second half of this year. A recycling merchant from Chengdu informed reporters from Caixin, “This year’s market conditions are poor. The price of Pian Zi Huang has dropped nearly 100 yuan per pill within a year.” A recycling merchant in Beijing also noted, “Before June of this year, the price of new An Gong Niu Huang Wan was around 600-650 yuan per pill, but it has dropped significantly in recent months.” Interviews with various recycling merchants revealed that since June, second-hand market prices have noticeably decreased. Currently, the price of new Pian Zi Huang is around 550 yuan per pill, while An Gong Niu Huang Wan (Tong Ren Tang’s dual-natural version) is priced between 450 and 500 yuan per pill. Expired or near-expiry ...
As one of the blue oceans in the field of autoimmune diseases , inflammatory bowel disease (IBD) treatment drugs are sought after and deployed by many multinational pharmaceutical companies. Recently, Eli Lilly acquired Morphic for US$3.2 billion and obtained its core pipeline α4β7 integrin inhibitor MORF-057, further expanding its influence in the field of gastrointestinal diseases. In addition to Eli Lilly, pharmaceutical giants including AbbVie, AstraZeneca, and Merck have laid out IBD treatment drugs and carried out related mergers and acquisitions. Behind the frequent actions, why do multinational pharmaceutical companies favor IBD treatment drugs so much? The dilemma of traditional treatment IBD is a chronic inflammatory bowel disease that mainly affects the digestive system. Its symptoms include severe diarrhea, frequent abdominal pain, blood in the stool, weight loss, and severe cancer. IBD mainly includes two types: ulcerative colitis (UC) and Crohn’s disease (CD). The two IBDs have both overlaps and ...
On September 18, Micro-Tech (NL) International B.V. announced that the company intends to use its own funds of no more than 36.72 million euros (equivalent to approximately 289 million yuan) to purchase 51% of the shares of Creo Medical S.L.U. (hereinafter referred to as “CME”) held by CreoMedical Group plc (hereinafter referred to as “Creo”) through its wholly-owned subsidiary Micro-Tech (NL) International B.V. After the completion of this transaction, CME will become a holding subsidiary of the company. The announcement shows that Creo is a medical device company headquartered in the UK and listed on the London Stock Exchange (stock code: CREO). Creo focuses on the development and commercialization of minimally invasive surgical equipment in the field of surgical endoscopy. Its main product is CROMA, an electrosurgical platform that can provide microwaves and bipolar radiofrequency for local cutting through a single accessory port, providing doctors with simplified and controllable surgical ...
Recently, Sinopharm Holdings issued an announcement on changes in the composition of the board committee, and Zhao Bingxiang was appointed as a non-executive director of Sinopharm. According to the process at the end of August, “the board of directors of Sinopharm has decided to elect Zhao Bingxiang as chairman of the board of directors. This appointment must be approved by shareholders at the shareholders’ meeting before the appointment of its non-executive director can take effect.” Zhao Bingxiang’s appointment as a non-executive director of Sinopharm also means that His appointment as chairman of the state-controlled company takes effect. At present, Sinopharm’s official website and announcement information have been updated, and Zhao Bingxiang serves as the chairman, non-executive director and party committee secretary of Sinopharm Holdings. It is reported that Zhao Bingxiang has worked in the China Resources department for a long time. He has served as a senior researcher at the ...
·ISM001-055 is an innovative drug driven by generative artificial intelligence and fully developed independently by Insilicon Intelligence. It targets TNIK (Traf2/NCK interacting kinase) and has completed phase IIa clinical trials for the treatment of patients with idiopathic pulmonary fibrosis (IPF); ·This study lasted for 12 weeks, and its preliminary results showed that ISM001-055 exhibited good safety in IPF patients and showed a dose-dependent pharmacological trend in improving lung function indicators in patients; ·The positive clinical trial results of ISM001-055 also provide the first conceptual validation for AI driven drug development. Hong Kong, China, September 18, 2024- Yingsi Intelligent, a clinical stage biotechnology company driven by generative artificial intelligence (AI), announced that its pipeline ISM001-055 has achieved positive preliminary research results in a phase IIa clinical trial. ISM001-055 is a “first in class” small molecule inhibitor driven by generative AI for drug discovery and design, targeting TNIK (Traf2/NCK interacting kinase) for ...
Motefutide Macau officially approvedOn September 20, 2024, Guangzhou Yuheng Biotechnology Co., Ltd. (referred to as “Yuheng Biotechnology”) announced the world’s first peptide drug, Mortifutide (APHEXDA), targeting the chemokine receptor 4 (CXC chemokine receptor 4, CXCR4) ®, Motixafortide has recently been officially approved for marketing by the Drug Administration of the Macao Special Administrative Region of China. According to the WHO ATC (Anatomical Therapeutic Chemical Classification System) drug classification management system, it has been approved as immune enhancer L03AX23, which is used in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells for peripheral blood stem cell collection and subsequent autologous transplantation in patients with multiple myeloma (MM). After Boao, Hainan, Macau has become the second region within Yuheng Biotech’s Asia authorized area to receive approval for Motefutide. Motefutide has obtained new drug approval in the United States in September 2023. It is the first approved innovative drug for ...
On September 19, the National Medical Products Administration (NMPA) released a public notice on its drug evaluation center’s official website, announcing that Lepu Biotech’s injection of Vebecotamab is proposed for priority review. This treatment is intended for patients with recurrent or metastatic nasopharyngeal carcinoma who have previously failed at least two lines of systemic chemotherapy and PD-1/PD-L1 inhibitor therapies. This drug, developed by Lepu Biotech, is an antibody-drug conjugate (ADC) targeting EGFR, with the development code MRG003. It is composed of an EGFR-targeted monoclonal antibody linked to a potent microtubule inhibitor, MMAE, through a vc linker. The molecular design of this drug has the potential to extend its application to a broader range of cancers that overexpress EGFR and may overcome various types of resistance caused by common mutations. In its previously published semi-annual report, Lepu Biotech indicated plans to submit a new drug application (NDA) for MRG003 to the ...
On September 14, according to the official website of CDE, AstraZeneca’s clinical trial application for the Class 1.1 chemical drug AZD5462 tablets was accepted. According to public information, the drug is a relaxin RXFP1 receptor agonist. Relaxin, as an agonist of the relaxin 1 receptor (RXFP1), produces unique and diverse biological effects, including pulmonary and systemic vasodilation, tissue remodeling/fibrosis reversal, and reduced inflammation, and therefore also has potential in cardiopulmonary diseases. significant curative effect. In addition, this substance is also known as the “pregnancy hormone” and is regulated during pregnancy to help the expectant mother’s cardiovascular system meet the increased demands of the developing fetus and remodel tissue and musculoskeletal structure. . AZD5462 is a relaxin RXFP1 receptor agonist developed by AstraZeneca. Preclinical studies on monkey models of heart failure with reduced ejection fraction (HFrEF) showed that cardiac systolic function was improved after 8 weeks of treatment. There was no ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.